Cover Image
市場調查報告書

心房纖維顫動:開發中產品分析

Atrial Fibrillation - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232800
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
心房纖維顫動:開發中產品分析 Atrial Fibrillation - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 97 Pages
簡介

所謂心房纖維顫動是指心跳數不規則(或是突然變快)的疾病,會成為人體內部血流停滯的原因。主要症狀有血壓降低及無力感、輕微的頭痛、意識不清、胸痛等。致病因素有年齡及心臟病、高血壓、家族病史、飲酒等。藥物治療、外科手術等是主要的治療法。

本報告提供治療全球各國的心房纖維顫動所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

心房纖維顫動概要

治療藥的開發

  • 心房纖維顫動開發中產品:概要
  • 心房纖維顫動開發中產品:比較分析

各企業開發中的心房纖維顫動治療藥

大學/研究機關研究中的心房纖維顫動治療藥

心房纖維顫動治療藥:開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

心房纖維顫動治療藥:開發中的產品一覽(各企業)

心房纖維顫動治療藥:研究中的產品一覽(各大學/研究機關)

心房纖維顫動開發治療藥的企業

  • ARCA biopharma, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Cardiome Pharma Corp.
  • 第一三共
  • Dong-A Socio Holdings Co. Ltd.
  • Gilead Sciences, Inc.
  • Laboratoires Pierre Fabre SA
  • 日產化學工業
  • OMEICOS Therapeutics GmbH
  • 大塚集團
  • Xention Limited

心房纖維顫動:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

心房纖維顫動治療藥:開發暫停的產品

心房纖維顫動治療藥:開發中止的產品

心房纖維顫動相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8335IDB

Summary

Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H2 2016', provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
  • The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects
  • The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Atrial Fibrillation Overview
  • Therapeutics Development
    • Pipeline Products for Atrial Fibrillation - Overview
    • Pipeline Products for Atrial Fibrillation - Comparative Analysis
  • Atrial Fibrillation - Therapeutics under Development by Companies
  • Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes
  • Atrial Fibrillation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Atrial Fibrillation - Products under Development by Companies
  • Atrial Fibrillation - Products under Investigation by Universities/Institutes
  • Atrial Fibrillation - Companies Involved in Therapeutics Development
    • ARCA biopharma, Inc.
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Cardiome Pharma Corp.
    • Daiichi Sankyo Company, Limited
    • Dong-A Socio Holdings Co. Ltd.
    • Gilead Sciences, Inc.
    • Laboratoires Pierre Fabre SA
    • Nissan Chemical Industries, Ltd.
    • OMEICOS Therapeutics GmbH
    • Otsuka Holdings Co., Ltd.
    • Xention Limited
  • Atrial Fibrillation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AFC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-919373 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bucindolol hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edoxaban tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-373280 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flecainide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIP-151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMT-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPC-108459 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-023725 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vernakalant hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEN-R0702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEND-0103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XENR-0703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XENR-0706 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Atrial Fibrillation - Dormant Projects
  • Atrial Fibrillation - Discontinued Products
  • Atrial Fibrillation - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study
      • May 02, 2016: New drug more effective in treating atrial fibrillation
      • Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation
      • Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session
      • Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA
      • Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia
      • Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant
      • Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015
      • Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation
      • Sep 23, 2015: UK's NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
      • Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing
      • Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China
      • Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice"
      • Jun 25, 2015: Daiichi Sankyo's Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
      • Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Atrial Fibrillation, H2 2016
  • Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H2 2016
  • Atrial Fibrillation - Pipeline by AstraZeneca Plc, H2 2016
  • Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Atrial Fibrillation - Pipeline by Cardiome Pharma Corp., H2 2016
  • Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
  • Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H2 2016
  • Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
  • Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H2 2016
  • Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2016
  • Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Atrial Fibrillation - Pipeline by Xention Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Atrial Fibrillation - Dormant Projects, H2 2016
  • Atrial Fibrillation - Dormant Projects (Contd..1), H2 2016
  • Atrial Fibrillation - Dormant Projects (Contd..2), H2 2016
  • Atrial Fibrillation - Dormant Projects (Contd..3), H2 2016
  • Atrial Fibrillation - Dormant Projects (Contd..4), H2 2016
  • Atrial Fibrillation - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Atrial Fibrillation, H2 2016
  • Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top